SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase II trial. - Motzer,R.J.; Rini,B.I.; Michaelson,M.D.; Redman,B.G.; Hudes,G.R.; Wilding,G.; Figlin,R.A.; Zhu,J.; Kim,S.T.; Baum,C. (Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2004)